Our target identification and validation solutions provide a comprehensive identification of where to target and parallel identification of off-target effects. Contact us today to learn how our team can help you achieve your therapeutic development goals.
Contact usTarget Discovery and Validation Solutions
Through the integration of our unique portfolio of assays and bioinformatics workflows, we provide unprecedented insights for the identification of disease-specific and accessible drug targets. After identifying an optimal target, we provide multidimensional evaluations of on- and off-target effects. Discover below how we provide the support needed for effective therapeutic development.
Target Discovery
and Validation
To be effective, a therapeutic has to target the right gene at the right location. To succeed in the clinic, off-targets need to be identified as soon as possible. With our unique portfolio of proprietary technologies, we provide solutions for holistic studies of target biology and therapeutic activity.
Contact usSmall molecules
ASOs
siRNA/shRNA
Aptamers
Find accessible regions to target
To be effective, therapeutics need to target unique and druggable regions of disease-causing genes. Learn how our solutions provide a comprehensive review of target biology allowing for optimal therapeutic design.
Identify open RNA structures
With our eSHAPE technology we can obtain validated information on the RNA secondary structure of a target gene. This structure information can be used to select drug candidates that target druggable pockets that are free of competition from proteins and miRNAs. It can also be used to directly measure where small molecules bind to a target RNA.
Predicted structures do not include the contribution of cellular factors that can limit accessibility. eSHAPE provides direct evaluation of structure in the cellular environment.
Locate unique druggable regions
With different diseases, a given gene can use different UTRs (regulatory regions outside the coding sequence). Our End-Seq technology directly identifies where UTRs are located, supporting the identification of druggable regions specific to the disease.
A 5’ UTR is more active in cancerous samples and not in healthy samples, making it a potential target for selective regulation in cancer.
Find protein effectors
RNA-binding proteins have been implicated in ASO activity and are frequent targets for small molecules and aptamers. With our RPB-eCLIP technology, we identify where a given protein binds across the transcriptome revealing information on potential proteins to block or mimic with small molecule drugs and to confirm protein activity for ASO efficacy.
Browser track showing the binding of a protein involved in splicing in the intron of RTEL1.
Validate
therapeutic effects
Many therapeutics have failed once they enter clinical trials due to limited on-target effects or problematic off-target effects. With our solutions we provide a holistic identification of on-target and off-target activity.
Identify off-target siRNA binding
Our miR-eCLIP technology identifies both miRNA and siRNA binding, making it a powerful tool for examining where and how off-target activity is happening. Off-target activity can occur through both seed-based binding and compensatory binding, and our technology identifies the binding mode to guide siRNA optimization.
Validated siRNA off-target binding in the coding sequence of the gene COPRS. The siRNA was designed to target the gene APP.
Transcription and translation effects
With eRibo Pro we directly measure changes in RNA expression (RNA-Seq) and translation (ribosome profiling), allowing for a comprehensive view of how a therapeutic affects cellular activity.
Identification of a stall in translation following treatment with the drug PF-846.
What our
partners say
"End-Seq assays are an invaluable part of our target assessment process at Ribometrix. The data are robust and often reveal novel 5’ and 3’ ends that aren’t reflected in public databases. Having this knowledge significantly influences strategic decisions around target selection in our RNA-targeting drug development process."
"Eclipsebio has been an invaluable partner to Deep Genomics. They've helped us generate massive miRNA-related datasets for training AI models, and have designed and conducted bespoke assays to illuminate the mechanism underlying some of our lead therapeutic compounds."
"Eclipsebio was instrumental in helping us characterize a small molecule-RNA interaction discovered by our platform. The Eclipsebio team worked closely with us to adapt their eSHAPE workflow to suit our needs, promptly delivered a complete data package, and generously followed-up."
“The Eclipsebio team guided us with their expertise to evaluate a few experimental options to meet our goal and provided a detailed report of the conducted experiment and analysis besides data files. Overall, our experience with Eclipsebio was fantastic and the outcome added great value to our project.”